## ADPT: Adaptive Biotechnologies Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -13.0% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-25.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($12.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $16 | $11 | +45% |
| 2025-11-06 | JP Morgan | $20 | $17 | +18% |
| 2025-11-06 | BTIG | $21 | $19 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |
| 2025-11-06 | JP Morgan | main | Overweight |
| 2025-11-06 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.16M) |
| Sells | 14 ($10.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-25.7% 5d) with bearish MACD, trend may be turning.
3. Heavy insider selling: $11M sold (14 transactions in 90 days).
4. Elevated short interest (8.2%): bears positioning against stock.
5. Near-term weakness: 9.1% below SMA50 despite long-term uptrend.

### Catalysts

- Analyst target momentum: 3 raises (avg +25%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Analyst sentiment positive (3 raises, avg +25%). Insider selling cluster ($10.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.5B |
| Beta | 2.20 |
| 52W Range | $5.91 - $20.76 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 12.8% to -13.0% (-25.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 17.0pp (needs >4.0% for momentum thesis). AM_20 at -11.0% indicates price below own 20MA trend. Underperforming sector by 10.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.27x) but short-term weakness (below SMA20). Elevated volume (1.9x 20MA), institutional activity likely. OFD pattern: -FTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -12.98% (CS: 1) | Weak |
| RSI_14 | 39.8 | Neutral |
| MACD Histogram | -0.19 | Bearish |
| vs SMA20 | 0.890x | Below |
| vs SMA50 | 0.909x | Below |
| vs SMA200 | 1.268x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $14.75
- **Stop Loss:** $12.19 (17.4% risk)
- **Target:** $17.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 195
- **Position Value:** $2,876.25
- **Portfolio %:** 2.88%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*